Trump wants Big Pharma to split MMR vaccine; Big Pharma thinks it's idiotic
US President Trump has suggested splitting the MMR vaccine, but the leading pharma group has rejected the idea.
- US President Trump has suggested splitting the MMR vaccine into separate injections.
- The leading pharma group has rejected the proposal, citing concerns over safety and efficacy.
- The controversy surrounding Trump's proposal highlights the importance of scientific evidence in informing public health policy.
US President Trump has sparked controversy with his suggestion that the MMR vaccine should be split into separate injections. The proposal, made in a recent statement, has been swiftly rejected by the leading pharma group. The group cited concerns over the safety and efficacy of such a move.
The MMR vaccine is a widely used vaccine that protects against measles, mumps, and rubella. Splitting the vaccine into separate injections could potentially lead to increased costs and logistical challenges.
The pharma industry's swift rejection of Trump's proposal highlights the importance of scientific evidence in informing public health policy. The move is also seen as a rare instance of the industry pushing back against a high-profile figure's suggestion.
The debate over vaccine policy is ongoing, with many experts arguing that the current vaccine schedule is safe and effective. The controversy surrounding Trump's proposal is likely to continue in the coming weeks and months.
The pharma industry's rejection of Trump's proposal is a significant development in the ongoing debate over vaccine policy. The move highlights the importance of scientific evidence in informing public health policy and the need for careful consideration of any changes to the current vaccine schedule.
The controversy surrounding Trump's proposal is likely to continue in the coming weeks and months, with many experts weighing in on the issue. The debate is complex and multifaceted, with many different perspectives and opinions on the table.
The pharma industry's rejection of Trump's proposal is a significant development in the ongoing debate over vaccine policy. The move highlights the importance of scientific evidence in informing public health policy and the need for careful consideration of any changes to the current vaccine schedule.
The controversy surrounding Trump's proposal is likely to continue in the coming weeks and months, with many experts weighing in on the issue. The debate is complex and multifaceted, with many different perspectives and opinions on the table.
This controversy highlights the ongoing debate over vaccine policy and the importance of scientific evidence in informing public health decisions.
NVIDIA AI Factory Compute Is Becoming an Investable Asset Class
Air Force explores AI tools to predict aircraft failures, strengthen sustainment - DefenseScoop
BusinessGemini becomes Google's fastest-growing product ever as it hits 1B users
BusinessChatGPT and Gemini both just passed 1 billion users
BusinessGoogle’s Gemini app surges to one billion users
SecurityDEF CON crowd suspected in fake-hotspot attack on Delta flight
The FBI is investigating a suspected fake Wi-Fi hotspot attack on a Delta flight, allegedly carried out by attendees at the DEF CON hacking conference.
AI ToolsMistral AI Regional Endpoints Bring EU and US Inference Controls to Enterprise Deployments
Mistral AI now offers regional inference endpoints in the EU and US, allowing enterprises to deploy AI models closer to their data for improved latency and compliance.
LLMThe End of Undetectable AI Text? Claude’s New Watermark Explained
Anthropic's Claude large language model has reportedly implemented a new watermarking technique designed to make AI-generated text more detectable, aiming to combat misinformation and enhance content authenticity.
USC Scientists Are Using Quantum Computing to Rethink Cancer Detection - USC Viterbi School of Engineering
USC scientists are leveraging quantum computing to revolutionize cancer detection methods.
FundingAccel closes oversubscribed $550M India fund within weeks, 19 months after its last
Accel closed a $550 million India fund in weeks, 19 months after its last one, with over half of the prior $650 million still unspent.
SecurityRussian drones found near vital European offshore gas site, get blown up
Russian drones were detected near a vital European offshore gas site and destroyed by Romanian authorities.